Previous 10 | Next 10 |
IVERIC bio (ISEE): Q4 GAAP EPS of -$0.27 misses by $0.01.Cash, cash equivalents and available for sale securities of $210M.FY21 guidance: cash, cash equivalents and available for sale securities will range between $130M-140M.Press Release For further details see: IVERIC bio EPS mis...
- Patient Enrollment for GATHER2 Clinical Trial of Zimura® for the Treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration Ahead of Target and Progressing Well; Completion of Enrollment Expected in 3Q of this Year - - Conference Call and Webcast Toda...
Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine. By focusing on CFH variants of Dry AMD, which represent over 6M patients in the US, the company is the first to bring a recombinant CFH into the clinic. Gemini's...
IVERIC bio, Inc. (Nasdaq:ISEE) today reported that on March 1, 2021, the Company granted non-statutory stock options to purchase an aggregate of 41,500 shares of the Company’s common stock to 2 newly hired, non-executive employees. These grants were made pursuant to the Compa...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, and Pravin U. Dugel, M.D., Chief Strategy and Business Officer, will participate in a fireside chat at the Cowen 41 st Annual Health Care Conference virtually on Thur...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m....
I look back on Kenneth Fisher's 1984 book Super Stocks and discuss its relevance today. Two value ratios - price-to-sales and price-to-research - are the foundation of Fisher's assessments. I've backtested a system based on his formula, and it still produces truly outsized returns...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39 th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021 at 2:50 p.m. East...
In my 2020 outlook, which was pre-coronavirus, I argued the case for buying small and microcap medical stocks that were priced for "non-success". This approach worked in 2020. My 2020 themes were gene therapy, targeted oncologics, and less invasive surgery. For 2021, I add SARS CoV-2 ...
IVERIC bio, Inc. (ISEE) Q3 2020 Earnings Conference Call November 02, 2020 8:00 AM ET Company Participants Kathy Galante - Investor Relations Glenn Sblendorio - Chief Executive Officer & President Dave Carroll - Chief Financial Officer Pravin Dugel - Chief Strategy & Business Officer ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...